POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

Completed · Phase 2

Conditions studied: Atopic Dermatitis

In brief

The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections. The study will enroll patients with moderate to severe AD to receive the 300 mg treatment. BSI-045B wil be firstly given weekly during Week 1 to Week 4, and then every 2 weeks (Q2W) to Week 24.

Key facts

Study ID
NCT05932654
Run by
Biosion, Inc.
People needed
22
Starts
2023-07-31
Expected to finish
2024-09-18
Last updated by the study team
2025-10-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.